Notably, the phase III trial in Japan targeted patients with Hb <10 g/dL, while our study focused on those with more severe anemia (Hb <8 g/dL), aligning with FDI's reimbursement indications in Japan. Here, GSTM1 is linked to anemia (phenotype).